Yang Ling, Zhang Shaojuan, Ling Xiaoxi, Shao Pin, Jia Ningyang, Bai Mingfeng
Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Department of Radiology, University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA 15219, USA.
Acta Biomater. 2017 May;54:271-280. doi: 10.1016/j.actbio.2017.03.012. Epub 2017 Mar 9.
Recent efforts to develop tumor-targeted photodynamic therapy (PDT) photosensitizers (PSs) have greatly advanced the potential of PDT in cancer therapy, although complete eradication of tumor cells by PDT alone remains challenging. As a way to improve PDT efficacy, we report a new combinatory PDT therapy technique that specifically targets multilayers of cells. Simply mixing different PDT PSs, even those that target distinct receptors (this may still lead to similar cell-killing pathways), may not achieve ideal therapeutic outcomes. Instead, significantly improved outcomes likely require synergistic therapies that target various cellular pathways. In this study, we target two proteins upregulated in cancers: the cannabinoid CB2 receptor (CBR, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor). We found that the CBR-targeted PS, IR700DX-mbc94, triggered necrotic cell death upon light irradiation, whereas PDT with the TSPO-targeted IR700DX-6T agent led to apoptotic cell death. Both PSs significantly inhibited tumor growth in vivo in a target-specific manner. As expected, the combined CBR- and TSPO-PDT resulted in enhanced cell killing efficacy and tumor inhibition with lower drug dose. The median survival time of animals with multilayer PDT treatment was extended by as much as 2.8-fold over single PDT treatment. Overall, multilayer PDT provides new opportunities to treat cancers with high efficacy and low side effects.
Photodynamic therapy (PDT) is increasingly used as a minimally invasive, controllable and effective therapeutic procedure for cancer treatment. However, complete eradication of tumor cells by PDT alone remains challenging. In this study, we investigate the potential of multilayer PDT in cancer treatment with high efficacy and low side effects. Through PDT targeting two cancer biomarkers located at distinct subcellular localizations, remarkable synergistic effects in cancer cell killing and tumor inhibition were observed in both in vitro and in vivo experiments. This strategy may be widely applied to treat various cancer types by using strategically designed PDT photosensitizers that target corresponding upregulated receptors at tactical subcellular localization.
尽管仅通过光动力疗法(PDT)完全根除肿瘤细胞仍然具有挑战性,但最近开发肿瘤靶向光动力疗法(PDT)光敏剂(PSs)的努力极大地推进了PDT在癌症治疗中的潜力。作为提高PDT疗效的一种方法,我们报告了一种新的联合PDT治疗技术,该技术专门针对多层细胞。简单地混合不同的PDT PSs,即使是那些靶向不同受体的PSs(这可能仍然导致相似的细胞杀伤途径),也可能无法实现理想的治疗效果。相反,显著改善的结果可能需要针对各种细胞途径的协同治疗。在这项研究中,我们靶向两种在癌症中上调的蛋白质:大麻素CB2受体(CBR,一种G蛋白偶联受体)和转位蛋白(TSPO,一种线粒体膜受体)。我们发现,靶向CBR的PS,IR700DX-mbc94,在光照下引发坏死性细胞死亡,而用靶向TSPO的IR700DX-6T试剂进行PDT则导致凋亡性细胞死亡。两种PSs均以靶点特异性方式在体内显著抑制肿瘤生长。正如预期的那样,联合CBR和TSPO-PDT以较低的药物剂量提高了细胞杀伤效力和肿瘤抑制效果。多层PDT治疗动物的中位生存时间比单一PDT治疗延长了多达2.8倍。总体而言,多层PDT为高效低副作用治疗癌症提供了新机会。
光动力疗法(PDT)越来越多地被用作一种微创、可控且有效的癌症治疗方法。然而,仅通过PDT完全根除肿瘤细胞仍然具有挑战性。在本研究中,我们研究了多层PDT在高效低副作用癌症治疗中的潜力。通过PDT靶向位于不同亚细胞定位的两种癌症生物标志物,在体外和体内实验中均观察到癌细胞杀伤和肿瘤抑制方面显著的协同效应。该策略可通过使用在策略性亚细胞定位靶向相应上调受体的策略性设计的PDT光敏剂广泛应用于治疗各种癌症类型。